Comparison · NCT02152982-sae
Arm II (Temozolomide, Veliparib) vs Arm I (Temozolomide, Placebo): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm II (Temozolomide, Veliparib) vs Arm I (Temozolomide, Placebo): serious adverse events. Trial comparisons, record NCT02152982-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02152982-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.197 | 0.15 | 0.255 | wilson | |
| Risk in group 2 | 0.221 | 0.17 | 0.281 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0234 | -0.1 | 0.0534 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.894 | 0.619 | 1.29 | log | |
| Odds ratio, group 1 over group 2 | 0.868 | 0.545 | 1.38 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm II (Temozolomide, Veliparib) than on Arm I (Temozolomide, Placebo) | 42.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm II (Temozolomide, Veliparib) | Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity. \> \> Laboratory Biomarker Analysis: Correlative studies \> \> Quality-of-Life Assessment: Ancillary studies \> \> Temozolomide: Given PO \> \> Veliparib: Given PO | 43 | 218 | EG001 |
| Group 2 | Arm I (Temozolomide, Placebo) | Patients receive temozolomide as in Arm II and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity. \> \> Laboratory Biomarker Analysis: Correlative studies \> \> Placebo Administration: Given PO \> \> Quality-of-Life Assessment: Ancillary studies \> \> Temozolomide: Given PO | 47 | 213 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All-Cause Mortality monitored/assessed for up to 83 months; Adverse Events monitored/assessed for up to 5 years
Source ClinicalTrials.gov
Trial
- Title
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- NCT number
- NCT02152982
- Phases
- PHASE2, PHASE3
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2023-04-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02152982?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02152982-sae